

## **Global Cell Therapy Market Report and Forecast 2023-2031**

Market Report | 2023-04-27 | 147 pages | EMR Inc.

### **AVAILABLE LICENSES:**

- Single User License \$5999.00
- Five User License \$7999.00
- Corporate License \$9999.00

### **Report description:**

Global Cell Therapy Market Report and Forecast 2023-2031

Global Cell Therapy Market Outlook

The global cell therapy market size attained a value of USD 13.8 billion in 2022. The market is likely to grow at a CAGR of 18.10% during the forecast period of 2023-2031 to attain a value of USD 61.2 billion by 2031.

Cell Therapy Market: Introduction

Cell therapy has emerged as a rapidly growing and innovative segment of the global healthcare industry. It encompasses a diverse range of therapeutic approaches, including regenerative medicine, immunotherapy, and gene therapy, aimed at treating various diseases and disorders by harnessing the power of living cells. The global cell therapy market is anticipated to witness significant growth in the coming years, driven by advancements in biotechnology, increasing investment in research and development, and a rising prevalence of chronic diseases and genetic disorders.

Factors like rising incidence of cancer, cardiovascular diseases, and autoimmune disorders drive the demand for innovative and effective treatment options, are fuelling the growth of the cell therapy market. Developments in gene editing technologies, such as CRISPR/Cas9, have opened new possibilities for cell therapies, offering improved efficacy and safety profiles. Governmental and private investments in cell therapy research have led to a robust pipeline of experimental treatments, which are expected to enter the market in the coming years.

Cell Therapy Market Segmentations

The market can be categorised into cell type, therapy type, therapeutic area, end user, and region.

Market by Cell Type

- Stem Cell
- o  Bone Marrow
- o  Blood

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com

- o□ Umbilical Cord
  - o□ Adipose Derived Stem Cell
  - o□ Others (Placenta, and Non-Specific Cells)
  - Non-Stem Cell
- Global Cell Therapy Market by Therapy Type

- Autologous
  - Allogeneic
- Market Breakup by Therapeutic Area

- Musculoskeletal
- Cardiovascular
- Gastrointestinal
- Neurological
- Oncology
- Dermatology
- Wounds and Injuries
- Ocular
- Others

- Market Breakup by End User
- Hospitals and Clinics
  - Regenerative Medicine Centres
  - Diagnostic and Research Centres
  - Others

Market Breakup by Region

- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- []Nigeria
- []South Africa
- []Others

## Cell Therapy Market Scenario

The cell therapy market is experiencing significant growth, driven by the increasing prevalence of chronic diseases, genetic disorders, and advancements in biotechnology. This burgeoning industry is marked by a highly competitive landscape, with major pharmaceutical and biotechnology companies, as well as smaller players and start-ups, vying for market share. Factors such as substantial investments in research and development, a strong pipeline of investigational therapies, and an expanding awareness of cell therapies' potential contribute to the market's expansion. However, challenges remain in the form of high treatment costs, ethical concerns, and regulatory hurdles. Nevertheless, the cell therapy market holds immense promise for revolutionizing the treatment landscape across various diseases and conditions.

## Key Players in the Global Cell Therapy Market

The report gives an in-depth analysis of the key players involved in the cell therapy market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

- []Vericel Corporation
- []Kolon TissueGene Inc.
- []CR Pharmaceuticals Co. Ltd.
- []MEDIPOST
- []Osiris
- []Stemmedica Cell Technologies Inc.
- []NuVasive Inc.
- []Fibrocell Science Inc.
- []Cellectis
- []Praxis Pharmaceutical
- []Genzyme Corporation
- []Advanced Tissue
- []Cells for Cells
- []PHARMICELL Co. Ltd
- []ANTEROGEN.CO.LTD.
- []Novartis AG,
- []GlaxoSmithKline plc,
- []CELGENE CORPORATION
- []Bone Therapeutics
- []Cell Therapies

## Table of Contents:

- 1 Preface
  - 1.1 Objectives of the Study
  - 1.2 Key Assumptions
  - 1.3 Report Coverage - Key Segmentation and Scope

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Cell Therapy Market Overview
  - 3.1 Global Cell Therapy Market Historical Value (2016-2022)
  - 3.2 Global Cell Therapy Market Forecast Value (2023-2031)
- 4 Global Cell Therapy Market Landscape
  - 4.1 Global Cell Therapy Developers Landscape
    - 4.1.1 Analysis by Year of Establishment
    - 4.1.2 Analysis by Company Size
    - 4.1.3 Analysis by Region
  - 4.2 Global Cell Therapy Product Landscape
    - 4.2.1 Analysis by Cell Type
    - 4.2.2 Analysis by Therapy Antigen
    - 4.2.3 Analysis by End User
- 5 Global Cell Therapy Market Dynamics
  - 5.1 Market Drivers and Constraints
  - 5.2 SWOT Analysis
  - 5.3 Porter's Five Forces Model
  - 5.4 Key Demand Indicators
  - 5.5 Key Price Indicators
  - 5.6 Industry Events, Initiatives, and Trends
  - 5.7 Value Chain Analysis
- 6 Global Cell Therapy Market Segmentation
  - 6.1 Global Cell Therapy Market by Cell Type
    - 6.1.1 Market Overview
    - 6.1.2 Stem Cell
      - 6.1.2.1 Bone Marrow
      - 6.1.2.2 Blood
      - 6.1.2.3 Umbilical Cord
      - 6.1.2.4 Adipose Derived Stem Cell
      - 6.1.2.5 Others (Placenta, and Non-Specific Cells)
    - 6.1.3 Non-Stem Cell
  - 6.2 Global Cell Therapy Market by Therapy Type
    - 6.2.1 Market Overview
    - 6.2.2 Autologous
    - 6.2.3 Allogeneic
  - 6.3 Global Cell Therapy Market by Therapeutic Area
    - 6.3.1 Market Overview
    - 6.3.2 Musculoskeletal disorders
    - 6.3.3 Cardiovascular diseases
    - 6.3.4 Neurological disorders
    - 6.3.5 Oncological disorders
    - 6.3.6 Dermatology
    - 6.3.7 Inflammatory and Autoimmune disorders
    - 6.3.8 Others
  - 6.4 Global Cell Therapy Market by End User
    - 6.4.1 Market Overview

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 6.4.2 Hospitals and Clinics
- 6.4.3 Regenerative Medicine Centers
- 6.4.4 Diagnostic and Research Centers
- 6.4.5 Others
- 6.5 Global Cell Therapy Market by Region
  - 6.5.1 Market Overview
  - 6.5.2 North America
  - 6.5.3 Europe
  - 6.5.4 Asia Pacific
  - 6.5.5 Latin America
  - 6.5.6 Middle East and Africa
- 7 North America Cell Therapy Market
  - 7.1 Market Share by Country
  - 7.2 United States of America
  - 7.3 Canada
- 8 Europe Cell Therapy Market
  - 8.1 Market Share by Country
  - 8.2 United Kingdom
  - 8.3 Germany
  - 8.4 France
  - 8.5 Italy
  - 8.6 Others
- 9 Asia Pacific Cell Therapy Market
  - 9.1 Market Share by Country
  - 9.2 China
  - 9.3 Japan
  - 9.4 India
  - 9.5 ASEAN
  - 9.6 Australia
  - 9.7 Others
- 10 Latin America Cell Therapy Market
  - 10.1 Market Share by Country
  - 10.2 Brazil
  - 10.3 Argentina
  - 10.4 Mexico
  - 10.5 Others
- 11 Middle East and Africa Cell Therapy Market
  - 11.1 Market Share by Country
  - 11.2 Saudi Arabia
  - 11.3 United Arab Emirates
  - 11.4 Nigeria
  - 11.5 South Africa
  - 11.6 Others
- 12 Patent Analysis
  - 12.1 Analysis by Type of Patent
  - 12.2 Analysis by Publication year
  - 12.3 Analysis by Issuing Authority

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 12.4 Analysis by Patent Age
- 12.5 Analysis by CPC Analysis
- 12.6 Analysis by Patent Valuation
- 12.7 Analysis by Key Players
- 13 Grants Analysis
  - 13.1 Analysis by year
  - 13.2 Analysis by Amount Awarded
  - 13.3 Analysis by Issuing Authority
  - 13.4 Analysis by Grant Application
  - 13.5 Analysis by Funding Institute
  - 13.6 Analysis by NIH Departments
  - 13.7 Analysis by Recipient Organization
- 14 Clinical Trials Analysis
  - 14.1 Analysis by Trial Registration Year
  - 14.2 Analysis by Trial Status
  - 14.3 Analysis by Trial Phase
  - 14.4 Analysis by Therapeutic Area
  - 14.5 Analysis by Geography
- 15 Funding Analysis
  - 15.1 Analysis by Funding Instances
  - 15.2 Analysis by Type of Funding
  - 15.3 Analysis by Funding Amount
  - 15.4 Analysis by Leading Players
  - 15.5 Analysis by Leading Investors
  - 15.6 Analysis by Geography
- 16 Partnership and Collaborations Analysis
  - 16.1 Analysis by Partnership Instances
  - 16.2 Analysis by Type of Partnership
  - 16.3 Analysis by Leading Players
  - 16.4 Analysis by Geography
- 17 Regulatory Framework
  - 17.1 Regulatory Overview
    - 17.1.1 US FDA
    - 17.1.2 EU EMA
    - 17.1.3 INDIA CDSCO
    - 17.1.4 JAPAN PMDA
    - 17.1.5 Others
- 18 Supplier Landscape
  - 18.1 Vericel Corporation
    - 18.1.1 Financial Analysis
    - 18.1.2 Product Portfolio
    - 18.1.3 Demographic Reach and Achievements
    - 18.1.4 Mergers and Acquisitions
    - 18.1.5 Certifications
  - 18.2 Kolon TissueGene Inc.
    - 18.2.1 Financial Analysis
    - 18.2.2 Product Portfolio

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 18.2.3 Demographic Reach and Achievements
- 18.2.4 Mergers and Acquisitions
- 18.2.5 Certifications
- 18.3 JCR Pharmaceuticals Co. Ltd.
  - 18.3.1 Financial Analysis
  - 18.3.2 Product Portfolio
  - 18.3.3 Demographic Reach and Achievements
  - 18.3.4 Mergers and Acquisitions
  - 18.3.5 Certifications
- 18.4 MEDIPOST Co. Ltd.
  - 18.4.1 Financial Analysis
  - 18.4.2 Product Portfolio
  - 18.4.3 Demographic Reach and Achievements
  - 18.4.4 Mergers and Acquisitions
  - 18.4.5 Certifications
- 18.5 Osiris
  - 18.5.1 Financial Analysis
  - 18.5.2 Product Portfolio
  - 18.5.3 Demographic Reach and Achievements
  - 18.5.4 Mergers and Acquisitions
  - 18.5.5 Certifications
- 18.6 Stemedica Cell Technologies Inc.
  - 18.6.1 Financial Analysis
  - 18.6.2 Product Portfolio
  - 18.6.3 Demographic Reach and Achievements
  - 18.6.4 Mergers and Acquisitions
  - 18.6.5 Certifications
- 18.7 NuVasive Inc.
  - 18.7.1 Financial Analysis
  - 18.7.2 Product Portfolio
  - 18.7.3 Demographic Reach and Achievements
  - 18.7.4 Mergers and Acquisitions
  - 18.7.5 Certifications
- 18.8 Fibrocell Science Inc.
  - 18.8.1 Financial Analysis
  - 18.8.2 Product Portfolio
  - 18.8.3 Demographic Reach and Achievements
  - 18.8.4 Mergers and Acquisitions
  - 18.8.5 Certifications
  - 18.8.6 Cells for Cells
  - 18.8.7 Financial Analysis
  - 18.8.8 Product Portfolio
  - 18.8.9 Demographic Reach and Achievements
  - 18.8.10 Mergers and Acquisitions
  - 18.8.11 Certifications
- 18.9 PHARMICELL Co. Ltd
  - 18.9.1 Financial Analysis

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 18.9.2 Product Portfolio
- 18.9.3 Demographic Reach and Achievements
- 18.9.4 Mergers and Acquisitions
- 18.9.5 Certifications
- 18.10 ANTEROGEN.CO.LTD.
  - 18.10.1 Financial Analysis
  - 18.10.2 Product Portfolio
  - 18.10.3 Demographic Reach and Achievements
  - 18.10.4 Mergers and Acquisitions
  - 18.10.5 Certifications
- 18.11 Novartis AG,
  - 18.11.1 Financial Analysis
  - 18.11.2 Product Portfolio
  - 18.11.3 Demographic Reach and Achievements
  - 18.11.4 Mergers and Acquisitions
  - 18.11.5 Certifications
- 18.12 CELGENE CORPO RATION
  - 18.12.1 Financial Analysis
  - 18.12.2 Product Portfolio
  - 18.12.3 Demographic Reach and Achievements
  - 18.12.4 Mergers and Acquisitions
  - 18.12.5 Certifications
- 18.13 Allogene Therapeutics Inc.
  - 18.13.1 Financial Analysis
  - 18.13.2 Product Portfolio
  - 18.13.3 Demographic Reach and Achievements
  - 18.13.4 Mergers and Acquisitions
  - 18.13.5 Certifications
- 18.14 Stempeutics Research Pvt. Ltd
  - 18.14.1 Financial Analysis
  - 18.14.2 Product Portfolio
  - 18.14.3 Demographic Reach and Achievements
  - 18.14.4 Mergers and Acquisitions
  - 18.14.5 Certifications
- 19 Global Cell Therapy Market - Distribution Model (Additional Insight)
  - 19.1 Overview
  - 19.2 Potential Distributors
  - 19.3 Key Parameters for Distribution Partner Assessment
- 20 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 21 Company Competitiveness Analysis (Additional Insight)
  - 21.1 Very Small Companies
  - 21.2 Small Companies
  - 21.3 Mid-Sized Companies
  - 21.4 Large Companies
  - 21.5 Very Large Companies
- 22 Payment Methods (Additional Insight)
  - 22.1 Government Funded

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 22.2 Private Insurance
- 22.3 Out-of-Pocket

**Global Cell Therapy Market Report and Forecast 2023-2031**

Market Report | 2023-04-27 | 147 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$5999.00
	Five User License	\$7999.00
	Corporate License	\$9999.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-02"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com